Skip to main content
. 2021 Oct;9(20):1562. doi: 10.21037/atm-21-4946

Figure 6.

Figure 6

The roles of THSD4 and PAPLN as potential prognostic biomarkers for ICI therapy in patients with NSCLC. (A and B) Kaplan-Meier survival curves showing estimates of PFS for comparisons of THSD4- (A) and PAPLN- (B) high-expression groups with their corresponding low-expression groups in 27 patients with advanced NSCLC who were treated with anti-PD-1/PD-L1. (C and D) Heatmap of differentially expressed proteins between THSD4- (C) or PAPLN- (D) high groups and their corresponding low-expression groups based on proteomic analysis of 18 patients with LUAD. (E) GO analysis of PAPLN-related proteins. ADAMTSLs, A disintegrin-like and metalloproteinase domain with thrombospondin type 1 motifs (ADAMTS)-like proteins; ICI, immune checkpoint inhibitor; NSCLC, non-small cell lung cancer; PFS, progression-free survival; LUAD, lung adenocarcinoma; GO, gene ontology; THSD4, thrombospondin type 1 domain containing 4; PAPLN, Papilin.